第一作者机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Liu Hong,Niu Shuhuai,Fang Zhaohui,et al.CAMRELIZUMAB MONOTHERAPY OR COMBINATION THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL AND ENDOMETRIAL CARCINOMA:A RETROSPECTIVE STUDY[J].JOURNAL FOR IMMUNOTHERAPY OF CANCER.2020,8:A109-A110.doi:10.1136/jitc-2020-SITC2020.0185.
APA：
Liu, Hong,Niu, Shuhuai,Fang, Zhaohui,Chen, Xi&Zhang, Qianying.(2020).CAMRELIZUMAB MONOTHERAPY OR COMBINATION THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL AND ENDOMETRIAL CARCINOMA:A RETROSPECTIVE STUDY.JOURNAL FOR IMMUNOTHERAPY OF CANCER,8,
MLA：
Liu, Hong,et al."CAMRELIZUMAB MONOTHERAPY OR COMBINATION THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL AND ENDOMETRIAL CARCINOMA:A RETROSPECTIVE STUDY".JOURNAL FOR IMMUNOTHERAPY OF CANCER 8.(2020):A109-A110
医学